Wird geladen...
Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report
RATIONALE: Nivolumab (Nivo) is an immune checkpoint inhibitor that has been used to treat advanced melanoma, nonsmall cell lung carcinoma, and renal cell carcinoma since 2015. Nivo is associated with several side effects, including hepatitis, pneumonitis, acute renal failure, endocrine disorder, and...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wolters Kluwer Health
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5502156/ https://ncbi.nlm.nih.gov/pubmed/28682883 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000007350 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|